Clinical

ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy.

While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and stronger multidisciplinary collaboration can significantly improve clinician confidence and real-world uptake.

Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for those with HER2 mutations.

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of Nefecon in patient care.

Visual acuity and central macular thickness improved in patients with diabetic macular edema who used combined phacoemulsification and intravitreal dexamethasone implants.

Influenza surveillance is essential to accurately measure disease burden, guide policy, and strengthen preparedness for future pandemics, according to Marco del Riccio, MD.

Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors.

Steven Stoner, PharmD, advises managed care teams to use rigorous diagnostic assessments, monitor adherence, and invest heavily in early patient follow-up to accurately attribute costs to treatment-resistant depression.

Explore the latest findings from the KATHERINE, PATINA, and HER2CLIMB-05 trials, highlighting advancements and challenges in breast cancer treatment.

Steven Stoner, PharmD, advocates for integrating patient-reported outcomes and digital monitoring to identify early treatment failure and justify utilizing highly effective therapies like dextromethorphan-bupropion sooner.

On average, patients with multiple prior dermatology visits still scored below 75% when identifying common skin cancer terms, underscoring the need for clearer patient-physician communication.

Methylprednisolone was more effective in treating thymoma compared with docetaxel but adverse effects were more common.

Explore the unique mechanisms of bispecific antibodies and their rapid availability compared to CAR T-cell therapies in cancer treatment.

Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications.

Patient–physician collaboration ensures trials reflect outcomes that matter to patients, according to Debra Patt, MD, PhD, MBA, MPH.

Last week, OpenAI launched AI tools for health care organizations, including ChatGPT for Healthcare, designed to improve care and streamline administrative tasks.

Risk-based vaccination strategies and clinical pathway integration could improve coverage and strengthen future influenza preparedness, according to Marco del Riccio, MD.

Amivantamab-vmjw combined with FOLFOX/FOLFIRI delivers encouraging response rates, durable benefit, and manageable safety.

Panelists discuss how emerging therapies targeting new pathways may revolutionize schizophrenia management.

Panelists discuss how optimizing safety and cost-efficiency are central to improving adherence and overall health care value.

Yara Abdou, MD, emphasizes that addressing fertility, survivorship, and quality of life is key to improving outcomes for young patients with breast cancer.

Although influenza vaccine uptake remains low, improving access, recommendations, and trust may help close coverage gaps.

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Reduced doses and shorter durations of venetoclax can enhance treatment outcomes and reduce adverse events in acute myeloid leukemia (AML).

Patients with unresectable stage III non–small cell lung cancer (NSCLC) had previously received neoadjuvant chemoimmunotherapy.